Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together

Area of Science:

• Urology
• Oncology
• Diagnostic Imaging

Background:

• Prostate cancer (PCa) diagnosis relies on serum total prostate specific antigen (tPSA) and digital rectal examination (DRE).
• Distinguishing between benign prostate hyperplasia (BPH) and PCa can be challenging, especially with borderline tPSA levels.
• Existing diagnostic markers require further evaluation for improved accuracy.

Purpose of the Study:

• To investigate the diagnostic value of serum tPSA-based parameters for prostate cancer (PCa).
• To evaluate the effectiveness of tPSA, free to tPSA ratio (f/tPSA), PSA density (PSAD), and PSA transition zone (PSAT) in differentiating BPH from PCa.
• To assess the utility of these parameters in patients with borderline tPSA or abnormal DRE findings.

Main Methods:

• Prospective study involving 110 BPH and 98 PCa patients.
• Evaluation of serum tPSA, f/tPSA, PSAD, and PSAT levels.
• Analysis of diagnostic performance, including sensitivity and specificity, with defined cut-off values.

Main Results:

• Significant differences in tPSA, f/tPSA, PSAD, and PSAT were observed between BPH and PCa groups.
• PSA transition zone (PSAT) showed discriminating power in patients with tPSA 4.1-9.9 ng/ml or abnormal DRE.
• Combined PSA parameters demonstrated high diagnostic specificity (92-93%) and sensitivity (84%).
• No single marker could definitively rule out or detect early PCa in the borderline tPSA group.

Conclusions:

• PSA-based parameters, particularly when used in combination, are valuable for PCa diagnosis and patient management.
• These markers aid in decision-making for biopsies, especially in cases with equivocal findings.
• Consideration of patient age and race is recommended when interpreting results for one or two positive PSA parameters.